Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Summary not available.
Summary not available.
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company dedicated to treating serious rare diseases, will host an investor and analyst event titled "The Future of Rare at Insmed" on May 8, 2023, from 8:00 a.m. to 12:00 p.m. ET in New York. The event will focus on Insmed's early-stage research programs and feature presentations from management and research leaders discussing their innovative platforms. The company aims to develop at least six new investigational new drug applications by 2025. A live webcast will be available on their website, with a replay accessible 30 minutes after the event's conclusion. Insmed's mission includes advancing therapies targeting unaddressed medical needs in rare pulmonary disorders and other serious conditions.
Insmed Incorporated (Nasdaq: INSM) announced it will release its first quarter 2023 financial results on May 4, 2023. A conference call for investors will be held at 8:30 a.m. ET on the same day to discuss the results and provide a business update.
Participants can join the call by dialing (833) 470-1428 for U.S. calls or (929) 526-1599 for international calls, using access code 468531. The call will also be available via a live webcast on Insmed's website.
A replay will be accessible after the call, lasting until June 3, 2023. Insmed is dedicated to treating serious and rare diseases with its approved therapies and an expanding pipeline.
On April 6, 2023, Insmed (Nasdaq: INSM) announced the granting of inducement awards to 24 new employees as per NASDAQ Listing Rule 5635(c)(4). The awards consist of options to purchase a total of 182,880 shares of common stock at an exercise price of $17.37, which corresponds to the closing trading price on the date of grant, April 3, 2023. The options feature a 10-year term and a four-year vesting schedule, with shares vesting incrementally over that period. Insmed is focused on transforming the lives of patients with serious and rare diseases, with its first commercial product approved in multiple regions to treat a chronic lung disease.
Insmed Incorporated (Nasdaq: INSM) has announced the completion of adult patient enrollment in its pivotal ASPEN study for brensocatib, a first-in-class treatment candidate for bronchiectasis. The Phase 3 study has enrolled over 1,700 patients aged 12 to 85 years, randomized into three groups for a 52-week treatment period. Topline data is expected in Q2 2024. Brensocatib, which has received Breakthrough Therapy Designation from the FDA, targets a market with no approved treatments and aims to alleviate the severe symptoms of bronchiectasis. The ongoing adolescent enrollment will not impact planned regulatory submissions.
Insmed, a biopharmaceutical company, announced eight presentations focusing on lung diseases at the American Thoracic Society (ATS) 2023 International Conference, scheduled for May 19-24, 2023, in Washington, D.C. Key highlights include:
- A qualitative interview study on amikacin liposome inhalation suspension (ARIKAYCE)
- Subgroup analysis of the Phase 2 WILLOW study on brensocatib in bronchiectasis patients
- Data on the hospitalization burden for patients with chronic obstructive pulmonary disease (COPD) and nontuberculous mycobacterial lung disease.
Insmed aims to address significant challenges in treating serious and rare lung diseases.
On March 3, 2023, Insmed announced the granting of inducement awards to 17 new employees as part of its hiring strategy. These awards, compliant with NASDAQ Listing Rule 5635(c)(4), involve options to purchase a total of 136,800 shares of Insmed common stock at an exercise price of $20.24 per share, the closing price on March 1, 2023. The options come with a 10-year term and a four-year vesting schedule, incentivizing employee retention and performance. Insmed focuses on transforming lives through therapies for serious and rare diseases.
Insmed, a biopharmaceutical company focused on rare diseases, announced its participation in two investor conferences. The first is the Cowen 43rd Annual Healthcare Conference, set for March 8, 2023, at 12:50 p.m. ET in Boston, followed by the Barclays Global Healthcare Conference on March 15, 2023, at 4:05 p.m. ET in Miami. Both presentations will feature fireside chats and will be available for live webcast on the company's investor relations website, archived for 30 days post-event. Insmed is committed to advancing therapies for serious unmet medical needs.
Insmed (Nasdaq: INSM) reported a strong financial performance for Q4 and FY 2022, with revenues of $59.3 million and $245.4 million, respectively, reflecting a 30% annual growth, primarily driven by ARIKAYCE sales. The company completed patient screening in the Phase 3 ASPEN trial for brensocatib and expects topline results in Q2 2024. Insmed anticipates ARIKAYCE revenues to reach $285-$300 million in 2023. Despite these gains, the company reported a net loss of $160.1 million in Q4 2022. With $1.15 billion in cash reserves, Insmed is well-positioned for sustained investment in its clinical programs.